Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TRIAMCINOLONE ACETONIDE

Form:

10 of 10 products shown

5 general benefit · 5 not a benefit

Other products in the same Health Canada class (D07AB, H02AB, R01AD) — coverage varies; not interchangeable

  • Beclomethasone dipropionate (Mylan-Beclo AQ): general benefit, Not a benefit
  • Budesonide (Rhinocort Aqua): general benefit, Not a benefit
  • Ciclesonide (Alvesco): general benefit
  • Desonide (Tridesilon): general benefit, Not a benefit
  • Dexamethasone (Decadron): general benefit, Not a benefit
  • Dexamethasone (Decadron): general benefit, Not a benefit

20 more in the class list below

Triaderm · DIN 00716960 · 0.1% · Cr

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Triaderm · DIN 00716960 Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01 Health Canada: Marketed since 1979-12-31 · brand TRIADERM CRM 0.1% · ATC D07AB09 TRIAMCINOLONE · form Cream · route Topical · ingredients TRIAMCINOLONE ACETONIDE 0.1 % · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Triaderm: Formulary list price $0.0533/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0533 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8573 · Verify on the e-Formulary ↗ (DIN 00716960)

Source record
DIN 00716960: Triaderm Raw flags: sec3=Y Item: 840600029; group id 850; item number 2067; lccId None; manufacturer id TAR Source form: Cr; strength: 0.1% Recorded listing: General benefit Source prices (unrounded): $0.0533; ministry $0.0533 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00716960 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8573
Interchangeable products
Aristocort R · DIN 02194058 · not recorded Kenalog · DIN 00029114 · not recorded
Shortage status: resolved shortage (ended 2022-12-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00716960
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Aristocort R · DIN 02194031 · 0.1% · Oint

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Aristocort R · DIN 02194031 Manufacturer: Valeo Pharma Inc.; listing date 1998-03-17 Health Canada: Marketed since 2020-11-24 · brand ARISTOCORT R · ATC D07AB09 TRIAMCINOLONE · form Ointment · route Topical · ingredients TRIAMCINOLONE ACETONIDE 0.1 %/W/W · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Aristocort R: Formulary list price $0.1856/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1856 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=35783 · Verify on the e-Formulary ↗ (DIN 02194031)

Source record
DIN 02194031: Aristocort R Raw flags: sec3=Y Item: 840600030; group id 850; item number 2068; lccId None; manufacturer id VAE Source form: Oint; strength: 0.1% Recorded listing: General benefit Source prices (unrounded): $0.1856; ministry $0.1856 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02194031 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=35783
Interchangeable products
Kenalog · DIN 01999796 · not recorded
Shortage status: resolved shortage (ended 2022-06-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02194031
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Kenalog-10 · DIN 01999761 · 50mg/5mL · injection suspension-5mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Kenalog-10 · DIN 01999761 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Marketed since 2009-12-02 · brand KENALOG-10 INJECTION · ATC H02AB08 TRIAMCINOLONE · form Suspension · route Intra-articular, Intrasynovial, Intrabursal, Intradermal · ingredients TRIAMCINOLONE ACETONIDE 10 MG/ML · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Kenalog-10: Formulary list price $19.4500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $19.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15482 · Verify on the e-Formulary ↗ (DIN 01999761)

Source record
DIN 01999761: Kenalog-10 Raw flags: sec3=Y Item: 680400035; group id 720; item number 1779; lccId None; manufacturer id BQU Source form: Inj Susp-5mL Pk; strength: 50mg/5mL Recorded listing: General benefit Source prices (unrounded): $19.4500; ministry $19.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01999761 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15482
Shortage status: active shortage (reported 2025-06-13, estimated to end 2026-12-31, last updated 2026-08-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999761
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Kenalog-40 · DIN 01999869 · 200mg/5mL · injection suspension-5mL Pk

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Kenalog-40 · DIN 01999869 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Marketed since 2010-11-23 · brand KENALOG-40 INJECTION · ATC H02AB08 TRIAMCINOLONE · form Suspension · route Intra-articular, Intramuscular · ingredients TRIAMCINOLONE ACETONIDE 40 MG/ML · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Kenalog-40: Formulary list price $31.6500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $31.6500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15481 · Verify on the e-Formulary ↗ (DIN 01999869)

Source record
DIN 01999869: Kenalog-40 Raw flags: sec3=Y Item: 680400034; group id 720; item number 1780; lccId None; manufacturer id BQU Source form: Inj Susp-5mL Pk; strength: 200mg/5mL Recorded listing: General benefit Source prices (unrounded): $31.6500; ministry $31.6500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01999869 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15481
Shortage status: active shortage (reported 2025-04-16, estimated to end 2026-12-31, last updated 2026-08-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999869
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Aristocort R · DIN 02194058 · 0.1% · Cr

Listed, not a benefitMarketed · checked 2026-09-02
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Aristocort R · DIN 02194058 Manufacturer: Valeant Canada Ltd.; listing date 1998-03-17 Health Canada: Marketed since 2020-11-24 · brand ARISTOCORT R · ATC D07AB09 TRIAMCINOLONE · form Cream · route Topical · ingredients TRIAMCINOLONE ACETONIDE 0.1 %/W/W · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Aristocort R: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=35784 · Verify on the e-Formulary ↗ (DIN 02194058)

Source record
DIN 02194058: Aristocort R Raw flags: notABenefit=Y, sec3=Y Item: 840600029; group id 850; item number 2067; lccId None; manufacturer id VAL Source form: Cr; strength: 0.1% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02194058 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=35784
Interchangeable products
Kenalog · DIN 00029114 · not recorded Triaderm · DIN 00716960 · $0.0533
Shortage status: resolved shortage (ended 2023-12-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02194058
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Triamcinolone AQ · DIN 02437635 · 55mcg/Metered Dose · Nas Sp-120 Dose Pk (with Preservative)

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Triamcinolone AQ · DIN 02437635 Manufacturer: Apotex Inc.; listing date 2016-08-30 Health Canada: Marketed since 2016-06-15 · brand APO-TRIAMCINOLONE AQ · ATC R01AD11 TRIAMCINOLONE · form Spray (metered-dose) · route Nasal · ingredients TRIAMCINOLONE ACETONIDE 55 MCG/ACT · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Triamcinolone AQ: Formulary list price $18.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $18.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92202 · Verify on the e-Formulary ↗ (DIN 02437635)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02437635). DIN 02437635: Apo-Triamcinolone AQ Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 520800036; group id 601; item number 1561; lccId None; manufacturer id APX Source form: Nas Sp-120 Dose Pk (with Preservative); strength: 55mcg/Metered Dose Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $18.0000; ministry $18.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437635 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92202
Interchangeable products
Nasacort AQ · DIN 02213834 · not recorded
Shortage status: active shortage (reported 2026-06-02, estimated to end 2026-10-16, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437635
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nasacort AQ · DIN 02213834 · 55mcg/Metered Dose · Nas Sp-120 Dose Pk (with Preservative)

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nasacort AQ · DIN 02213834 Manufacturer: Sanofi Consumer Health Inc.; listing date 2016-08-30 Health Canada: Marketed since 2022-07-16 · brand NASACORT AQ · ATC R01AD11 TRIAMCINOLONE · form Spray (metered-dose) · route Nasal · ingredients TRIAMCINOLONE ACETONIDE 55 MCG/ACT · company Sanofi consumer health inc · schedule Prescription
Check this DIN again · Health Canada product record

Nasacort AQ: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19807 · Verify on the e-Formulary ↗ (DIN 02213834)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02213834). DIN 02213834: Nasacort AQ Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 520800036; group id 601; item number 1561; lccId None; manufacturer id SCO Source form: Nas Sp-120 Dose Pk (with Preservative); strength: 55mcg/Metered Dose Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02213834 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19807
Interchangeable products
Apo-Triamcinolone AQ · DIN 02437635 · $18.0000
Shortage status: resolved shortage (ended 2021-07-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02213834
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Kenalog-40 · PIN 00990876 · 40mg/mL · injection suspension-1mL Pk

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 01999869 (Marketed, 2010-11-23) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15481

Check Health Canada brand DIN
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Kenalog-40 · DIN 00990876 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 01999869 (Marketed, 2010-11-23) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15481
Check this DIN again

Kenalog-40: Formulary list price $8.9610/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.9610 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00990876)

Source record
DIN 00990876: Kenalog-40 Raw flags: sec3=Y Item: 680400036; group id 720; item number 1778; lccId None; manufacturer id BQU Source form: Inj Susp-1mL Pk; strength: 40mg/mL Recorded listing: General benefit Source prices (unrounded): $8.9610; ministry $8.9610 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00990876 Health Canada record for this brand: DIN 01999869 (Marketed, 2010-11-23) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15481
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00990876
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Kenalog · PIN 00029114 · 0.1% · Cr

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Kenalog · DIN 00029114 Manufacturer: Westwood Squibb Pharmaceuticals; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Kenalog: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00029114)

Source record
DIN 00029114: Kenalog Raw flags: notABenefit=Y, sec3=Y Item: 840600029; group id 850; item number 2067; lccId None; manufacturer id WSQ Source form: Cr; strength: 0.1% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00029114 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Aristocort R · DIN 02194058 · not recorded Triaderm · DIN 00716960 · $0.0533
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00029114
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Kenalog · DIN 01999796 · 0.1% · Oint

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-08-05 — choose a marketed DIN from the same-category list.Discontinued 2004-08-05 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-08-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2004-08-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Kenalog · DIN 01999796 Manufacturer: Westwood Squibb Pharmaceuticals; listing date 1996-10-01 Health Canada: Cancelled post market since 2004-08-05 · brand KENALOG OINTMENT 0.1% · ATC D07AB09 TRIAMCINOLONE · form Ointment · route Topical · ingredients TRIAMCINOLONE ACETONIDE 1 MG/G · company Westwood-squibb, division of bristol-myers squibb canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Kenalog: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19868 · Verify on the e-Formulary ↗ (DIN 01999796)

Source record
DIN 01999796: Kenalog Raw flags: notABenefit=Y, sec3=Y Item: 840600030; group id 850; item number 2068; lccId None; manufacturer id WSQ Source form: Oint; strength: 0.1% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01999796 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19868
Interchangeable products
Aristocort R · DIN 02194031 · $0.1856
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999796
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2004-08-05 — choose a marketed DIN from the same-category list.

TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE

1 general benefit · 1 not a benefit

Other products in the same Health Canada class (D07AB, H02AB, R01AD) — coverage varies; not interchangeable

  • Beclomethasone dipropionate (Mylan-Beclo AQ): general benefit, Not a benefit
  • Budesonide (Rhinocort Aqua): general benefit, Not a benefit
  • Ciclesonide (Alvesco): general benefit
  • Desonide (Tridesilon): general benefit, Not a benefit
  • Dexamethasone (Decadron): general benefit, Not a benefit
  • Dexamethasone (Decadron): general benefit, Not a benefit

20 more in the class list below

Oracort · DIN 01964054 · · Oral Top Oint

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Oracort · DIN 01964054 Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01 Health Canada: Marketed since 2021-10-12 · brand ORACORT · ATC A01AC01 TRIAMCINOLONE · form Paste · route Dental · ingredients TRIAMCINOLONE ACETONIDE 0.1 % · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

Oracort: Formulary list price $1.5607/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.5607 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13360 · Verify on the e-Formulary ↗ (DIN 01964054)

Source record
DIN 01964054: Oracort Raw flags: sec3=Y Item: 840600034; group id 851; item number 2069; lccId None; manufacturer id TAR Source form: Oral Top Oint; strength: None Recorded listing: General benefit Source prices (unrounded): $1.5607; ministry $1.5607 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01964054 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13360
Interchangeable products
Kenalog-Orabase · DIN 01999788 · not recorded
Shortage status: resolved shortage (ended 2020-04-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01964054
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Kenalog-Orabase · DIN 01999788 · · Oral Top Oint

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-09-04 — choose a marketed DIN from the same-category list.Discontinued 2008-09-04 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-09-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-09-04 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Kenalog-Orabase · DIN 01999788 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2008-09-04 · brand KENALOG IN ORABASE 0.1% · ATC A01AC01 TRIAMCINOLONE · form Paste · route Dental · ingredients TRIAMCINOLONE ACETONIDE 1 MG/G · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Kenalog-Orabase: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14583 · Verify on the e-Formulary ↗ (DIN 01999788)

Source record
DIN 01999788: Kenalog-Orabase Raw flags: notABenefit=Y, sec3=Y Item: 840600034; group id 851; item number 2069; lccId None; manufacturer id BQU Source form: Oral Top Oint; strength: None Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01999788 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14583
Interchangeable products
Oracort · DIN 01964054 · $1.5607
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999788
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2008-09-04 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (52:08 Anti-Inflammatory Agents) and how they are covered

Matched class: 52:08 Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DEXAMETHASONE, FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, KETOROLAC TROMETHAMINE, LODOXAMIDE TROMETHAMINE Some products covered without a code (check the product listing): BECLOMETHASONE DIPROPIONATE, BUDESONIDE, PREDNISOLONE ACETATE 52:08 Anti-Inflammatory Agents

BECLOMETHASONE DIPROPIONATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 50mcg · Nas-Sp-200 Dose Pk

BUDESONIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 64mcg/Metered Dose, 100mcg/Metered Dose · Nas Sp-120 Dose Pk, Nas Sp-165 Dose Pk

AZELASTINE HCL & FLUTICASONE PROPIONATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 137mcg/Actuation&50mcg/Actuation · Nas-Sp-120 Dose Pk

FLUTICASONE PROPIONATE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Actuation · Nas Sp-120 Dose Pk

MOMETASONE FUROATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Dose · Nas Sp-140 Dose Pk

DEXAMETHASONE

· 2 products · General benefit · strengths: 0.1% · Oph Oint-3.5g Pk, Oph Susp

FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN

· 1 products · General benefit · strengths: 0.02% & 1% · Ot Sol

FLUOROMETHOLONE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

FLUOROMETHOLONE ACETATE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

KETOROLAC TROMETHAMINE

· 3 products · General benefit · strengths: 0.5%, 0.45% w/v · Oph Sol, Oph Sol-0.4mL Vial Pk (Preservative-Free)

LODOXAMIDE TROMETHAMINE

· 1 products · General benefit · strengths: 0.1% · Oph Sol

PREDNISOLONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Oph Susp Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:08 and 2 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors, 52:36 Other Eye, Ear, Nose and Throat Agents

Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L

PREDNISONE

· 7 products · General benefit (5), Listed, not a benefit (2) · strengths: 1mg, 5mg, 50mg · Tab

TRIAMCINOLONE HEXACETONIDE

· 1 products · Limited Use, codes 580 · strengths: 20mg/mL · 1mL-Amp Pk

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids

Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered

Matched class: 84:06 Anti-Inflammatory

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE 84:06 Anti-Inflammatory

DESONIDE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.05% · Cr, Oint

AMCINONIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.1% · Cr

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 0.025% · Cr, Oint

BETAMETHASONE DIPROPIONATE

· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint

BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL

· 2 products · General benefit · strengths: 0.05% · Oint

BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE

· 2 products · General benefit · strengths: 0.05% · Cr

BETAMETHASONE VALERATE

· 19 products · Listed, not a benefit (7), General benefit (12) · strengths: 0.05%, 0.1% · Cr, Lot, Oint, Scalp Lot

CLOBETASOL PROPIONATE

· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp

FLUOCINONIDE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 0.05% · Cr, Emol Cr, Gel, Oint

HALOBETASOL PROPIONATE

· 1 products · General benefit · strengths: 0.01% w/w · Lot

HYDROCORTISONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.5%, 1% · Oint

HYDROCORTISONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06 and 4 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:28 Keratolytic Agents, 84:36 Miscellaneous Skin and Mucous Membrane Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no link
What the Health Canada label says it is for
Product monograph unavailable: no link

Availability

Kenalog-10 · DIN 01999761 Shortage status: active shortage (reported 2025-06-13, estimated to end 2026-12-31, last updated 2026-08-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999761

Check this DIN again

Kenalog-40 · DIN 01999869 Shortage status: active shortage (reported 2025-04-16, estimated to end 2026-12-31, last updated 2026-08-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999869

Check this DIN again

Apo-Triamcinolone AQ · DIN 02437635 Shortage status: active shortage (reported 2026-06-02, estimated to end 2026-10-16, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437635

Check this DIN again

Other review policies

For Aristocort R, Apo-Triamcinolone AQ, Nasacort AQ, Kenalog, Kenalog-Orabase: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026